-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Jul 11

PMID 32645963

Citations 9

Authors

Lisa Belfiore

Darren N Saunders

Marie Ranson

Kara L Vine

Affiliations

Soon will be listed here.

Abstract

The urokinase plasminogen activator and its receptor (uPA/uPAR) are biomarkers for metastasis, especially in triple-negative breast cancer. We prepared anti-mitotic -alkylisatin (-AI)-loaded liposomes functionalized with the uPA/uPAR targeting ligand, plasminogen activator inhibitor type 2 (PAI-2/SerpinB2), and assessed liposome uptake in vitro and in vivo. Receptor-dependent uptake of PAI-2-functionalized liposomes was significantly higher in the uPA/uPAR overexpressing MDA-MB-231 breast cancer cell line relative to the low uPAR/uPAR expressing MCF-7 breast cancer cell line. Furthermore, -AI cytotoxicity was enhanced in a receptor-dependent manner. In vivo, PAI-2 -AI liposomes had a plasma half-life of 5.82 h and showed an increased accumulation at the primary tumor site in an orthotopic MDA-MB-231 BALB/c-Fox1nu/Ausb xenograft mouse model, relative to the non-functionalized liposomes, up to 6 h post-injection. These findings support the further development of -AI-loaded PAI-2-functionalized liposomes for uPA/uPAR-positive breast cancer, especially against triple-negative breast cancer, for which the prognosis is poor and treatment is limited.

Citing Articles

Advancements in mitochondrial-targeted nanotherapeutics: overcoming biological obstacles and optimizing drug delivery.

Li Y, Li X, Wei L, Ye J Front Immunol. 2024; 15:1451989.

PMID: 39483479 PMC: 11524880. DOI: 10.3389/fimmu.2024.1451989.

Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.

Hamada M, Varkoly K, Riyadh O, Beladi R, Munuswamy-Ramanujam G, Rawls A Biomedicines. 2024; 12(6).

PMID: 38927374 PMC: 11201033. DOI: 10.3390/biomedicines12061167.

Functionalized liposomes for targeted breast cancer drug delivery.

Nel J, Elkhoury K, Velot E, Bianchi A, Acherar S, Francius G Bioact Mater. 2023; 24:401-437.

PMID: 36632508 PMC: 9812688. DOI: 10.1016/j.bioactmat.2022.12.027.

Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy.

Rethi L, Mutalik C, Anurogo D, Lu L, Chu H, Yougbare S Nanomaterials (Basel). 2022; 12(17).

PMID: 36079985 PMC: 9458017. DOI: 10.3390/nano12172948.

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.

Zhai B, Tian H, Sun J, Zou J, Zhang X, Cheng J J Transl Med. 2022; 20(1):135.

PMID: 35303878 PMC: 8932206. DOI: 10.1186/s12967-022-03329-3.

References

Vine K, Indira Chandran V, Locke J, Matesic L, Lee J, Skropeta D . Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth. Curr Cancer Drug Targets. 2011; 12(1):64-73. DOI: 10.2174/156800912798888983. View

Messerschmidt S, Kolbe A, Muller D, Knoll M, Pleiss J, Kontermann R . Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling. Bioconjug Chem. 2007; 19(1):362-9. DOI: 10.1021/bc700349k. View

Colombo M, Fiandra L, Alessio G, Mazzucchelli S, Nebuloni M, De Palma C . Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. Nat Commun. 2016; 7:13818. PMC: 5187442. DOI: 10.1038/ncomms13818. View

Mazar A, Ahn R, OHalloran T . Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des. 2011; 17(19):1970-8. PMC: 3188847. DOI: 10.2174/138161211796718152. View

Herda L, Hristov D, Giudice M, Polo E, Dawson K . Mapping of Molecular Structure of the Nanoscale Surface in Bionanoparticles. J Am Chem Soc. 2016; 139(1):111-114. DOI: 10.1021/jacs.6b12297. View

Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R . Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 1994; 33(7):779-86. DOI: 10.3109/02841869409083948. View

Kessler R, FANESTIL D . Interference by lipids in the determination of protein using bicinchoninic acid. Anal Biochem. 1986; 159(1):138-42. DOI: 10.1016/0003-2697(86)90318-0. View

Huber M, Mall R, Braselmann H, Feuchtinger A, Molatore S, Lindner K . uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. BMC Cancer. 2016; 16:615. PMC: 4977758. DOI: 10.1186/s12885-016-2663-9. View

Caujolle F, Caujolle D, Cros S, CALVET M . Limits of toxic and teratogenic tolerance of dimethyl sulfoxide. Ann N Y Acad Sci. 1967; 141(1):110-26. DOI: 10.1111/j.1749-6632.1967.tb34871.x. View

10.

Croucher D, Saunders D, Stillfried G, Ranson M . A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells. Biochem J. 2007; 408(2):203-10. PMC: 2267350. DOI: 10.1042/BJ20070767. View

11.

Belfiore L, Spenkelink L, Ranson M, van Oijen A, Vine K . Quantification of ligand density and stoichiometry on the surface of liposomes using single-molecule fluorescence imaging. J Control Release. 2018; 278:80-86. DOI: 10.1016/j.jconrel.2018.03.022. View

12.

Keam B, Im S, Kim H, Oh D, Kim J, Lee S . Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007; 7:203. PMC: 2217558. DOI: 10.1186/1471-2407-7-203. View

13.

Xiao K, Li Y, Luo J, Lee J, Xiao W, Gonik A . The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011; 32(13):3435-46. PMC: 3055170. DOI: 10.1016/j.biomaterials.2011.01.021. View

14.

Willis , Forssen . Ligand-targeted liposomes. Adv Drug Deliv Rev. 2000; 29(3):249-271. DOI: 10.1016/s0169-409x(97)00083-5. View

15.

Conese M, Blasi F . Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol Chem Hoppe Seyler. 1995; 376(3):143-55. View

16.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

17.

Duffy M, McGowan P, Harbeck N, Thomssen C, Schmitt M . uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2015; 16(4):428. PMC: 4423643. DOI: 10.1186/s13058-014-0428-4. View

18.

Harris N, Vennin C, Conway J, Vine K, Pinese M, Cowley M . SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene. 2017; 36(30):4288-4298. PMC: 5537606. DOI: 10.1038/onc.2017.63. View

19.

Cochran B, Croucher D, Lobov S, Saunders D, Ranson M . Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer. J Biol Chem. 2011; 286(27):24467-75. PMC: 3129226. DOI: 10.1074/jbc.M111.225706. View

20.

Ivascu A, Kubbies M . Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol. 2007; 31(6):1403-13. View